Research ArticleAUTOIMMUNITY

How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes

See allHide authors and affiliations

Science Immunology  05 Apr 2019:
Vol. 4, Issue 34, eaav7517
DOI: 10.1126/sciimmunol.aav7517

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • RE: Superagonist diabetogenic peptides
    • Felix Mor, Scientist, Weizmann Institute of Science

    I read with great interest the work by Wang and colleagues on the superagonist diabetogenic peptides. The structural work is extensive and very impressive. However, I would expect to see evidence on the pathophysiological implications of these neopeptides beyond their inducing a stronger proliferation of diabetogenic T cells. Does immunization with these novel fusion peptides in CFA (as compared to native B9-23) induce Diabetes in prediabetic NOD mice? If the T cells reactive to these peptides are pathogenic in NOD mice, will stimulation with the novel fusion peptides (as compared to B9-23) result in more severe disease in the recipients? Does stimulation with these peptides result in a more polarized Th1/Th17 phenotype?

    Competing Interests: None declared.

Stay Connected to Science Immunology

Navigate This Article